PTC Therapeutics Announces Impressive Financial Performance and Key Updates for 2025 PTC Therapeutics reported significant financial results for 2025, featuring product revenues of $831 million, boosted by Sephience's successful launch and promising growth.

PTC Therapeutics Announces Impressive Financial Performance and Key Updates for 2025 #USA #PTC_Therapeutics #Warren #Sephience #Evrysdi

Get the latest on Evrysdi’s 5-year data—read more here: https://bit.ly/3T3pFJ3

#SMA #Evrysdi #Research #SMANews #Bionews

Roche suffers a fresh blow as India's Supreme Court allows generic sales of its pricey rare disease drug The decision is a victory for patient advocates aiming to increase access to cheaper treatments for SMA.

Roche suffers a fresh blow as India’s Supreme Court allows generic sales of its pricey rare disease drug.. statnews.com/pharmalot/20... #pharma #Roche #raredisease #generics #India #Evrysdi